Evidence map›Paper›PMID 32582179›Full record

ReviewFrontiers in immunology2020

CD2 Immunobiology.

Christian Binder, Filip Cvetkovski, Felix Sellberg, Stefan Berg, Horacio Paternina Visbal, David H Sachs, Erik Berglund, David Berglund

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 151 citations in OpenAlex.

  1. Design of aptamer peptides for immunomodulation.Journal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Christian BinderDepartment of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden.
Filip CvetkovskiResearch and Development, ITB-Med AB, Stockholm, Sweden.
Felix SellbergDepartment of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden.
Stefan BergResearch and Development, ITB-Med AB, Stockholm, Sweden.
Horacio Paternina VisbalDepartment of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden.
David H SachsResearch and Development, ITB-Med AB, Stockholm, Sweden.
Erik BerglundResearch and Development, ITB-Med AB, Stockholm, Sweden.
David BerglundDepartment of Immunology, Genetics and Pathology, Section of Clinical Immunology, Uppsala University, Uppsala, Sweden.
Swedish Orphan Biovitrum (Sweden) · SEColumbia University Irving Medical Center · USKarolinska Institutet · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The glycoprotein CD2 is a costimulatory receptor expressed mainly on T and NK cells that binds to LFA3, a cell surface protein expressed on e.g., antigen-presenting cells. CD2 has an important role in the formation and organization of the immunological synapse that is formed between T cells and antigen-presenting cells upon cell-cell conjugation and associated intracellular signaling. CD2 expression is upregulated on memory T cells as well as activated T cells and plays an important role in activation of memory T cells despite the coexistence of several other costimulatory pathways. Anti-CD2 monoclonal antibodies have been shown to induce immune modulatory effects

Indexed as

AnimalsCD2 AntigensHumansImmunological SynapsesLymphocyte ActivationT-LymphocytesCD2 AntigensAlefaceptCD2CD58costimulationcostimulation blockadeLFA-3 (lymphocyte functional antigen-3)siplizumabT cell activation

Identifiers

PMID32582179
PMCPMC7295915
OpenAlexW4211151548

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.